News

CMN Weekly (7 January 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Jan. 7, 2022

Top Picks

Research

Industry

Detection

  • American researchers have developed a highly sensitive CRISPR-Cas12a immuno-assay to detect CXCL9 in urine from kidney transplant patients. CXCL9 in the urine is a biomarker for acute rejection episodes, but it isn't easy to detect with traditional ELISA assays. The new immuno-CRISPR assay used anti-CXCL9 antibody-DNA barcode conjugates and amplified fluorescent signals via Cas12a-based trans-cleavage activity of FQ reporter substrates. As a result, a detection limit of 14 pg/mL of CTXL9 was achieved, equivalent to a ~7-fold increase compared to ELISA.

Reviews

Huh, Huh, Wow

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN WeeklyHashtagLipid-based nanoparticleHashtagAdenovirus (AV)HashtagAcute Myeloid Leukemia, AMLHashtagHereditary angioedema, HAEHashtagSickle Cell Disease, SCDHashtagAutoimmune diseaseHashtagBlood diseaseHashtagCancerHashtagOther Genetic ConditionsHashtagGene therapyHashtaganticrispr proteinsHashtagBase editorsHashtagCas12aHashtagCas9HashtagZFN - Zinc finger nucleasesHashtagArbor BiotechnologiesHashtagCellectis S.A.HashtagIntellia Therapeutics, Inc.HashtagKyverna TherapeuticsHashtagONK TherapeuticsHashtagSangamo Therapeutics Inc.HashtagSanofi S.AHashtagTCR2 TherapeuticsHashtagClinical

Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine